This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vogel, V. G. Search for Related Content PubMed PubMed Citation Articles by Vogel, V. G. Social Bookmarking                            What's this?

Reducing the Risk of Breast Cancer With Tamoxifen in Women at Increased Risk

From the Magee-Women’s Hospital, University of Pittsburgh Cancer Institute Breast Program, University of Pittsburgh, Pittsburgh, PA.

Address reprint requests to Victor G. Vogel, MD, MHS, University of Pittsburgh Cancer Institute/Magee-Women’s Hospital, 300 Halket St, Rm 3524, Pittsburgh, PA 15213; email: vvogel{at}mail.magee.edu

ABSTRACT: Validated quantitative models are available that permit the accurate estimation of a woman’s risk of developing invasive breast cancer during a specified period of time. Data from the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial indicate that tamoxifen can reduce the risk of developing breast cancer by at least 49% in women who are at increased risk. All premenopausal women whose 5-year risk of developing breast cancer is 1.67% or greater derive a net benefit from taking tamoxifen for risk reduction. Women who have either lobular carcinoma-in-situ or atypical ductal or lobular hyperplasia derive an even greater net benefit. Women who carry mutations in either the BRCA1 or BRCA2 gene will also experience reduced incidence of breast cancer with tamoxifen. Although postmenopausal women derive a net benefit from tamoxifen through the reduction of both breast cancer and bone fracture event rates, the risks of both invasive endometrial cancer and thromboembolic events must be balanced in older women. Physicians should identify appropriate candidates with whom to discuss the possible benefits of tamoxifen for reducing the risk of breast cancer.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				V. G. Vogel and S. Lo Preventing Hormone-Dependent Breast Cancer in High-Risk Women J Natl Cancer Inst, January 15, 2003; 95(2): 91 - 93. [Full Text] [PDF]